1.
The Influence of a blend of Probiotic Lactobacillus and Prebiotic Inulin on the Duration and Severity of Symptoms among Individuals with Covid-19
Gavin Publishers is an international open access journal publishers. We publish research, review, mini review, case report, case series, editorial, short communication, opinion, perspective, rapid communication, commentary, and brief report peer reviewed articles in best Clinical, Medical, Pharma, Life Sciences, and Engineering Subject Journals. All our journals are Double Blind Peer Reviewed Journals and our website have more than 10 Million readers, all papers publishing in our Journals are globally accepted. Our conferences have more than 5000 renowned Speakers combined in an event with interactive sessions and Poster presentations. Gavin Publishers is combination of Journals and Conferences, currently we are publishing articles in more than 150+ best Journals and organizing 100 Conferences all over the world. Our open access journals committed to disseminating top notch academic research and academic journals throughout the world covering various disciplines of science, technology and medicine.
2024
Abstract
Gut microbial irregularities can lead to increased gut inflammation and gut membrane damage in people with long covid. Symptoms such as cough and breathlessness are apparent in Covid 19 patients with harmful gut bacterial overgrowth. In Covid patients, antibiotic and dexamethasone treatment also aggravates gut microbial imbalances. Lactobacillus supplementation has been shown to lessen upper respiratory tract infection, increase gut bacterial diversity, improve gut wall integrity, reduce gastrointestinal symptoms and gut inflammation, decrease oxidative stress and improve immunity. This study analysed the efficacy of probiotics and prebiotics combined supplements in reducing the severity and longevity of symptomatic Covid infection. 126 participants with Covid symptoms consumed two capsules a day for a month of a supplement containing 5 species of Lactobacillus and chicory inulin. 32% of participants were in the early phase of infection, and 68% were in the late phase. Both early and late phase participants showed significant improvements in cough, fatigue, and subjective wellbeing after 30 days of intervention. The gut symptoms of 82% of the participants improved after a month of intervention. Inulin and Lactobacillus strains need to be studied further robustly to determine whether they provide additional benefits. Healthcare practitioners can use the results of this study to consider symbiotic interventions for those with Covid symptoms.
2.
The Problem of ‘Long Haul’ COVID
Scientific American covers the advances in research and discovery that are changing our understanding of the world and shaping our lives. Founded 1845, it is the oldest continuously published magazine in the United States and now reaches more than 10 million people around the world each month through its website, print and digital editions, newsletters and app.
2021
Abstract
Long COVID is very real and its chronic health manifestations can be quite debilitating. This article aims to shed light on the complications of this syndrome, which is affecting a significant number of individuals. The persistent effects are wide-ranging and include cognitive issues like brain fog and memory/attention problems, shortness of breath, increased heart rate, nausea, diarrhea, intermittent spiking fevers. Authors report that much more research and care provision strategies are urgently needed in order to tackle the post-viral pandemic we are facing.
3.
Panic Attacks: Biology or Psychology?
Dr. Mark Hyman is a practicing family physician and an internationally recognised leader, speaker, educator, and advocate in the field of Functional Medicine. He is the founder and director of The UltraWellness Center, the Head of Strategy and Innovation of the Cleveland Clinic Center for Functional Medicine, a thirteen-time New York Times bestselling author, and Board President for Clinical Affairs for The Institute for Functional Medicine.
2021
Abstract
In this episode, Dr Hyman and Dr George Papaicolaou discuss the Functional Medicine approach to treating panic attacks. They explore the range of physiological considerations encountered when treating patients who are experiencing panic attacks, as well as how adverse childhood experiences (ACEs) and trauma can be treated to reduce anxiety and eliminate panic attacks.
4.
Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot dose-ranging study.
Wölnerhanssen, BK, Drewe, J, Verbeure, W, le Roux, CW, Dellatorre-Teixeira, L, Rehfeld, JF, Holst, JJ, Hartmann, B, Tack, J, Peterli, R, et al
Diabetes, obesity & metabolism. 2021;23(6):1311-1321
-
-
-
Free full text
-
Plain language summary
In recent years, erythritol, a non-calorie sweetener, has gained popularity due to the rise in obesity and Type 2 diabetes worldwide. The purpose of this randomised, placebo-controlled, double-blind, cross-over trial was to assess the effects of erythritol on the release of gut hormones, speed of gastric emptying, and the release of glucagon, motilin, and glucose-dependent insulinotropic polypeptide after erythritol administration. Erythritol in doses of ten, twenty-five, and fifty grams was well tolerated by the participants. The administration of erythritol induced a statistically significant dose-dependent stimulation of gut hormones such as plasma cholecystokinin, active glucagon‐like peptide‐1 and peptide tyrosine. Compared to the placebo, participants had slower gastric emptying with erythritol. Erythritol had no effect on the levels of motilin, glucose-dependent insulinotropic polypeptide, blood glucose, insulin, glucagon, blood lipids, or uric acid. Erythritol should be evaluated in larger, robust studies to determine whether it improves glycaemic control. However, healthcare professionals can use the results of this study to understand the potential uses of erythritol in the management of obesity and type 2 diabetes.
Abstract
AIM: To determine whether a dose-dependent effect in the stimulation of gut hormone release (plasma cholecystokinin [CCK], active glucagon-like peptide-1 [aGLP-1] and peptide tyrosine tyrosine [PYY]) is found for the natural sweetener erythritol. MATERIALS AND METHODS Twelve healthy, lean volunteers received solutions with 10, 25 or 50 g erythritol, or tap water enriched with 13 C-sodium acetate on four study days via a nasogastric tube in this randomized (active treatments), placebo-controlled, double-blind, cross-over trial. Blood samples and breath samples (13 C-sodium acetate method for measurement of gastric emptying [GE]) were taken at regular intervals, and sensations of appetite and gastrointestinal symptoms were rated. RESULTS We found (a) a dose-dependent stimulation of CCK, aGLP-1 and PYY, and slowing of GE, (b) no effect on blood glucose, insulin, motilin, glucagon or glucose-dependent insulinotropic polypeptide, (c) no effect on blood lipids and uric acid, and (d) no abdominal pain, nausea or vomiting. CONCLUSIONS Solutions with 10 and 50 g of erythritol stimulated gut hormone release. Emptying of erythritol-containing solutions from the stomach was slower compared with placebo. There was no effect on plasma glucose, insulin, glucagon, blood lipids or uric acid. All doses were well tolerated.